GSK3326595 (Standard)

GSK3326595 (Standard) is the analytical standard of GSK3326595 (HY-101563) . This product is intended for research and analytical applications. GSK3326595 is a protein arginine methyltransferase 5 (PRMT5) inhibitor. GSK3326595 decreases SARS-CoV-2 infection, inhibits cancer cell proliferation and induces pro-inflammatory macrophage polarization and increases hepatic triglyceride levels without affecting atherosclerosis. GSK3326595 can be used for research of relapsed/refractory mantle cell lymphoma[1][2][3][4][5].

Product Specifications

CAS Number

[1616392-22-3]

Target

Apoptosis; CDK; Histone Methyltransferase; MDM-2/p53; Reference Standards; SARS-CoV

Related Pathways

Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Others

Field of Research

Cancer; Infection

Smiles

O=C(C)N1CCC(NC2=NC=NC(C(NC[C@H](O)CN3CCC(C=CC=C4)=C4C3)=O)=C2)CC1

Molecular Formula

C24H32N6O3

Molecular Weight

452.55

References & Citations

[1]Li Z, et al. GSK3326595 is a promising drug to prevent SARS-CoV-2 Omicron and other variants infection by inhibiting ACE2-R671 di-methylation [J]. Journal of Medical Virology, 2023, 95 (1) : e28158.|[2]Fedoriw A, et al. Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss [J]. Cancer cell, 2019, 36 (1) : 100-114. e25.|[3]Zhang Y, et al. PRMT5 inhibition induces pro‐inflammatory macrophage polarization and increased hepatic triglyceride levels without affecting atherosclerosis in mice [J]. Journal of Cellular and Molecular Medicine, 2023, 27 (8) : 1056-1068.|[4]Che Y, et al. Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations [J]. Blood cancer journal, 2023, 13 (1) : 27.|[5]Luo Y, et al. Myelocytomatosis-protein arginine N-methyltransferase 5 Axis defines the tumorigenesis and immune response in hepatocellular carcinoma [J]. Hepatology, 2021, 74 (4) : 1932-1951.